7-溴吲哚-2-羧酸 | 16732-71-1

• 物质功能分类: 医药中间体 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-溴吲哚-2-羧酸
• 英文名称: 7-bromo-1H-indole-2-carboxylic acid
• 英文别名: 7-Brom-indol-2-carbonsaeure
• CAS: 16732-71-1
• 化学式: C₉H₆BrNO₂
• 分子量: 240.056
• InChiKey: ZKGMXVLKFBRKNN-UHFFFAOYSA-N

物化性质

• 熔点：
  238-243°C
• 沸点：
  470.9±25.0 °C(Predicted)
• 密度：
  1.838±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319
• 危险性防范说明：
  P305 + P351 + P338
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-1h-indole-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-1h-indole-2-carboxylic acid
CAS number: 16732-71-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H6BrNO2
Molecular weight: 240.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：重要的医药中间体

反应信息

• 作为反应物：
  描述：

  7-溴吲哚-2-羧酸 在 喹啉 、 copper(I) bromide 作用下， 生成 7-溴吲哚
  参考文献：
  名称：

  Pappalardo; Vitali, Gazzetta Chimica Italiana, 1958, vol. 88, p. 1147,1153, 1159

  摘要：

  DOI：
• 作为产物：
  描述：

  Pyruvinsaeure-(o-brom-phenylhydrazon)-ethylester 在 PPA 、 alkaline solution 作用下， 生成 7-溴吲哚-2-羧酸
  参考文献：
  名称：

  Pappalardo; Vitali, Gazzetta Chimica Italiana, 1958, vol. 88, p. 1147,1153, 1159

  摘要：

  DOI：

文献信息

• Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis
  作者：Shaohua Hou、Xiping Yang、Yu Tong、Yuejing Yang、Quanwei Chen、Boheng Wan、Ran Wei、Yuchen Wang、Yanmin Zhang、Bo Kong、Jianhang Huang、Yadong Chen、Tao Lu、Qinghua Hu、Ding Du

  DOI：10.1016/j.ejmech.2020.113114

  日期：2021.2

  compound 19 with a novel indole-2-carboxamide hinge scaffold. Compound 19 displays potent anti-ASK1 kinase activity and stronger inhibitory effect on ASK1 in AP1-HEK293 cells than previously described ASK1 inhibitor GS-4997. Besides improved in vitro activity, compound 19 also exhibits an appropriate in vivo PK profile. In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound

  凋亡信号调节激酶1（ASK1）是丝裂原激活的蛋白激酶（MAPK）家族的成员，与许多人类疾病有关。在这里，我们描述了命中化合物7的结构优化，并进行了进一步的结构-活性关系（SAR）研究，从而开发了带有新型吲哚-2-羧酰胺铰链支架的化合物19。与先前描述的ASK1抑制剂GS-4997相比，化合物19在AP1-HEK293细胞中显示出强大的抗ASK1激酶活性和对ASK1的更强抑制作用。除了改善体外活性外，化合物19还具有适当的体内活性PK配置文件。在右旋糖酐硫酸钠（DSS）诱导的溃疡性结肠炎（UC）小鼠模型中，化合物19显示出显着的抗UC功效，并显着减轻了DSS诱导的体重减轻，结肠缩短，疾病活动指数（DAI）升高和炎症结肠组织中的细胞浸润。从机理上讲，化合物19抑制ASK1-p38 / JNK信号通路的磷酸化，并抑制炎症细胞因子的过表达。这些发现共同表明，ASK1抑制剂可以潜在地用作UC的治疗策略。
• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RECEPTEURS ACTIVES PAR LES PROLIFERATEURS DE PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2005054176A1

  公开（公告）日：2005-06-16

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式（I）的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉粥样硬化以及其他与X综合征和心血管疾病相关的疾病。
• Synthesis of 3,3-Dihalo-2-oxindoles from 2-Substituted Indoles <i>via</i> Halogenation-Decarboxylation/Desulfonamidation-Oxidation Process
  作者：Xiaojian Jiang、Feng Zhang、Junjie Yang、Pei Yu、Peng Yi、Yewei Sun、Yuqiang Wang

  DOI：10.1002/adsc.201600771

  日期：2016.12.22

  A novel one‐pot reaction which combines halogenation, decarboxylation/desulfonamidation with oxidation has been developed. Diverse valuable 3,3‐dihalo‐2‐oxindole compounds can be produced rapidly and safely with isolated yields of up to 98% under mild conditions.

  已开发出一种新颖的单锅反应，该反应将卤化，脱羧/脱磺酰胺化与氧化反应相结合。在温和的条件下，可以快速安全地生产出各种有价值的3,3-二卤代-2-氧吲哚化合物，分离产率高达98％。
• [EN] CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS<br/>[FR] DÉRIVÉS PENTACYCLIQUES CONDENSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'INFECTIONS DE FLAVIVIRIDAE
  申请人：GENELABS TECH INC

  公开号：WO2009086139A1

  公开（公告）日：2009-07-09

  Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds and compositions are useful for treating viral infections caused by the Flaviviridae family of viruses.

  提供的是式（I）的化合物或其药学上可接受的盐或溶剂。这些化合物和组合物可用于治疗由黄病毒科病毒引起的病毒感染。
• 一种炔类化合物、制备方法及其应用
  申请人：北京赛特明强医药科技有限公司

  公开号：CN109988151B

  公开（公告）日：2021-04-23

  本发明属于化学医药领域，具体涉及式(I)化合物或其药学可接受的盐、异构体、溶剂合物、结晶或前药，以及含有这些化合物的药物组合物和这些化合物或组合物在药物制备中的应用。这类化合物及其药学上可接受的盐、异构体、溶剂合物、结晶或前药等形态可用于许多不同的癌症及其它疾病的治疗或预防。